1

2

3

4
Dai Yujia, Davidsen Steven K, Ericsson Anna M, Hartandi Kresna, Ji Zhiqin, Michaelides Michael R: Indazole, benzisoxazole, and benzisothiazole kinase inhibitors. Abbott Laboratories, Dai Yujia, Davidsen Steven K, Ericsson Anna M, Hartandi Kresna, Ji Zhiqin, Michaelides Michael R, STEELE Gregory, December 29, 2004: WO/2004/113304 (37 worldwide citation)

Compounds having the formula (I) are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.


5
George Dawn M, Wang Lu, Li Biqin, Ericsson Anna M, Ansell Graham K: Octahydropentalene compounds as chemokine receptor antagonists. Abbott Laboratories, George Dawn M, Wang Lu, Li Biqin, Ericsson Anna M, Ansell Graham K, O BRIEN Gayle B, April 2, 2009: WO/2009/042193 (22 worldwide citation)

The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts thereof, pro-drugs thereof, biologically active metabolites thereof, isomers thereof or stereoisomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as ...


6

7

8

9
Ericsson Anna, Marinier Anne, Zusi Fred C: Compounds having retinoid-like activity. Bristol Myers Squibb Company, Ericsson Anna, Marinier Anne, Zusi Fred C, GIBBONS Maureen, August 29, 2002: WO/2002/065984

There are provided compounds represented by formula (I) or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, wherein the various substituents are as defined. Also included are methods for preventing and/or treating tumors, arthritis, and non-malignan ...


10
Doyle Kevin J, Rafferty Paul, Steele Robert W, Wilkins David J, Hockley Michael, Arnold Lee D, Ericsson Anna M: Tricyclic pyrazole derivatives. Basf Aktiengesellschaft, Doyle Kevin J, Rafferty Paul, Steele Robert W, Wilkins David J, Hockley Michael, Arnold Lee D, Ericsson Anna M, WAGNER Richard W, May 18, 2000: WO/2000/027822

This invention relates to certain 3-aryl or 3-heteroaryl pyrazoles with 4,5(3,4)-bicyclic ring fusion which are inhibitors of protein kinase activity, of which some are novel compounds, to pharmaceutical compositions containing these pyrazoles and to processes for preparing these pyrazoles.